Answers are grounded in this paper and cite their sources.
Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis. We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis. Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and to a lesser extent with aspergillosis. Continued investigation into the use of triple therapy against mucormycosis and aspergillosis is warranted.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: